Showing results (171-180 of 182) with videos related to

Sort By:
Pageof 19
Angiology|January 3, 2024
Fully Automated Agatston Score Calculation From Electrocardiography-Gated Cardiac Computed Tomography Using Deep Learning and Multi-Organ Segmentation: A Validation StudyAshish Gautam, Prashant Raghav, Vijay Subramaniam, et al.
Clinical Lung Cancer|November 21, 2021
The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung CancerMisako Nagasaka, Vijendra Singh, Yasmine Baca, et al.
Iscience|March 27, 2023
Identification of actionable targets for breast cancer intervention using a diversity outbred mouse modelJennifer B Jacob, Kuang-Chung Wei, Gerold Bepler, et al.
Journal of Oncology Practice|March 2, 2012
Quality of care in non-small-cell lung cancer: findings from 11 oncology practices in FloridaTawee Tanvetyanon, Michelle Corman, Ji-Hyun Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|September 5, 2021
Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)Misako Nagasaka, Mohammad Fahad B Asad, Mohammed Najeeb Al Hallak, et al.
Therapeutic Advances in Medical Oncology|November 10, 2025
Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1, or KRAS: the TRITON studyFerdinandos Skoulidis, Hossein Borghaei, Edward B Garon, et al.
Leukemia & Lymphoma|August 27, 2020
Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapyDavid Straus, Graham Collins, Jan Walewski, et al.
Molecular Cell|June 3, 2014
HDAC6 deacetylates and ubiquitinates MSH2 to maintain proper levels of MutSαMu Zhang, Shengyan Xiang, Heui-Yun Joo, et al.
Haematologica|June 24, 2021
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 studyAndrew M Evens, Joseph M Connors, Anas Younes, et al.
Hematological Oncology|January 19, 2021
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 studyMartin Hutchings, John Radford, Stephen M Ansell, et al.
Pageof 19